Treatment Selection for Urolithiasis: Percutaneous Nephrolithomy, Ureteroscopy, Shock Wave Lithotripsy, and Active Monitoring
Overview
Authors
Affiliations
Urolithiasis is a significant worldwide source of morbidity, constituting a common urological disease that affects between 10 and 15% of the world population. Recent technological and surgical advances have replaced the need for open surgery with less invasive procedures. The factors which determine the indications for percutaneous nephrolithotomy include stone factors (stone size, stone composition, and stone location), patient factors (habitus and renal anomalies), and failure of other treatment modalities (ESWL and flexible ureteroscopy). The accepted indications for PCNL are stones larger than 20 mm, staghorn and partial staghorn calculi, and stones in patients with chronic kidney disease. The contraindications for PCNL include pregnancy, bleeding disorders, and uncontrolled urinary tract infections. Flexible ureteroscopy can be one of the options for lower pole stones between 1.5 and 2 cm in size. This option should be exercised in cases of difficult lower polar anatomy and ESWL-resistant stones. Flexible ureteroscopy can also be an option for stones located in the diverticular neck or a diverticulum. ESWL is the treatment to be discussed as a option in all patient with renal stones (excluding lower polar stones) between size 10 and 20 mm. In addition, in lower polar stones of size between 10 and 20 mm if the anatomy is favourable, ESWL is the option. In proximal ureteral stones, ESWL should be considered as a option with flexible ureteroscopy Active monitoring has a limited role and can be employed in post-intervention (PCNL or ESWL) residual stones, in addition, asymptomatic patients with no evidence of infection and fragments less than 4 mm can be monitored actively.
Guo J, Chen X, Yi X, Dou Y, Xiong Y, Zhao T Front Endocrinol (Lausanne). 2025; 16:1460682.
PMID: 40078581 PMC: 11896853. DOI: 10.3389/fendo.2025.1460682.
Xu M, Jin L, Yang D, Xue B, Sun C, Tao W Urolithiasis. 2025; 53(1):37.
PMID: 39985595 PMC: 11846721. DOI: 10.1007/s00240-025-01699-z.
Aghamir S, Farsani R, Shamshirgaran A, Ahamdi N, Chivaee H, Mashhadi R Am J Clin Exp Urol. 2024; 12(5):279-287.
PMID: 39584008 PMC: 11578771. DOI: 10.62347/BHLM2937.
Zong Y, Zhu Y, Han P, Wang Z, Pu J, Gu M Lasers Med Sci. 2024; 39(1):258.
PMID: 39400745 DOI: 10.1007/s10103-024-04209-6.
Kumar N, Somani B Arab J Urol. 2024; 22(3):159-165.
PMID: 38818256 PMC: 11136457. DOI: 10.1080/20905998.2024.2309780.